KIORA PHARMACEUTICALS INC (KPRX, KPHMW) — SEC Form D Filing

KIORA PHARMACEUTICALS INC (KPRX, KPHMW) filed an SEC Form D on April 21, 2026, reporting $5.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
April 21, 2026
Amount reported
$5.00M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://kiorapharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Kiora Pharmaceuticals addresses vision-threatening retinal diseases such as retinitis pigmentosa and retinal inflammation, where current treatments are limited or non-effective.

Solution

Kiora Pharmaceuticals is developing therapies like KIO-301 and KIO-104. KIO-301 is a light-activated molecular photoswitch designed to restore vision by enabling retinal ganglion cells to detect light in retinitis pigmentosa, while KIO-104 is a next-generation anti-inflammatory for retinal diseases targeting T-cell driven inflammation without steroid side effects.

Why now

There is an urgent demand for new therapies to treat retinal diseases, particularly as existing treatments are inadequate.

Verdict

Investors said yes at the time because Kiora Pharmaceuticals presented an innovative approach to address critical gaps in retinal disease treatment, not simply because it followed the standard pharmaceutical narrative. They were implicitly betting on the urgency of unmet medical needs creating a ready market for effective therapies with a novel mechanism. However, the limited upside lies in the competitive landscape with large incumbents and potential regulatory hurdles, making durability uncertain.

Source: SEC EDGAR Form D filing